Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.

Diabetes Care · 2013 · PMC3554310 · PMID 22966091

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

A borderline significant risk decrease was observed for metformin, with HR 0.87 (0.79–0.96) in model 2 and 0.87 (0.78–0.97) in model 3, and sulfonylureas as well, with 0.89 (0.81–0.97) and 0.86 (0.77–0.95).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.